India's Vaccine Maitri- a Unique Friendship
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
What Do We Know About India's Covaxin Vaccine?
FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year. -
India - the Netherlands Virtual Summit Friday, April 9, 2021
India - The Netherlands Virtual Summit Friday, April 9, 2021 Joint Statement on India-The Netherlands Virtual Summit - Towards a Strategic Partnership on Water Shri Narendra Modi, Prime Minister of the Republic of India, and H.E. Mr. Mark Rutte, Prime Minister of the Netherlands, co-chaired a Virtual Summit between India and the Netherlands on April 9, 2021. 2. The two Prime Ministers recalled their previous meetings in 2015, 2017 and 2018 as well as the successful visit of the King and the Queen of the Netherlands to India in 2019 and welcomed the steadfast development of bilateral relations that are underpinned by the shared values of democracy, rule of law, pluralism, equality, freedom of speech and respect for human rights and the historic bonds of friendship between the two countries. They held an in- depth exchange of views on further deepening the bilateral relationship in wide-ranging areas of cooperation including trade and economy, water management and agriculture sector, smart cities and urban mobility, science & technology cooperation, public health & health care and space. 3. In the context of new geopolitical and geoeconomic realities, they also shared views on regional and global issues of mutual interest including post-Covid economic recovery, climate change and the Indo-Pacific. They reiterated their strong commitment to a rules- based multilateral order for ensuring international peace, stability and prosperity. Fight against COVID-19 Pandemic 4. The two leaders commended the selfless contribution of healthcare workers and other frontline staff across the globe in the fight against the pandemic. Both leaders reiterated their commitment to ensure equitable and affordable access to Covid19 vaccines to all countries and agreed to cooperate in this regard. -
Download File (Pdf)
2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION 2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION Foreword by Mo Ibrahim Notwithstanding these measures, on current projections Founder and Chair of the Mo Ibrahim Africa might not be adequately covered before 2023. Foundation (MIF) Vaccinating Africa is an urgent matter of global security and all the generous commitments made by Africa’s partners must now be delivered. Looking ahead - and inevitably there will be future pandemics - Africa needs to significantly enhance its Over a year ago, the emergence and the spread of COVID-19 homegrown vaccine manufacturing capacity. shook the world and changed life as we knew it. Planes were Africa’s progress towards its development agendas was off grounded, borders were closed, cities were shut down and course even before COVID-19 hit and recent events have people were told to stay at home. Other regions were hit created new setbacks for human development. With very earlier and harder, but Africa has not been spared from the limited access to remote learning, Africa’s youth missed out pandemic and its impact. on seven months of schooling. Women and girls especially The 2021 Ibrahim Forum Report provides a comprehensive are facing increased vulnerabilities, including rising gender- analysis of this impact from the perspectives of health, based violence. society, politics, and economics. Informed by the latest data, The strong economic and social impacts of the pandemic it sets out the challenges exposed by the pandemic and the are likely to create new triggers for instability and insecurity. -
In 2020, India Dealt with the First Wave of COVID-19 Pandemic With
PREFACE n 2020, India dealt with the first wave of COVID-19 pandemic with collective measures, Iscientific approach, and awareness. Undoubtedly the second wave of the pandemic is testing our patience and the extent to which we can all tolerate its fangs. The impact of the second wave has seen shortage of medical oxygen across the nation. But, the intelligent use of technology and well-planned resource allocation to tackle the new wave of the pandemic has been dealt with at a war-footing. The current edition, COVID 2021: Nation’s S&T Efforts Against COVID-19, has been compiled to inform our readers and strengthen the usefulness of any published information. This edition contains compilation and coverage of information related to the capacity enhancement of medical oxygen, start-up spotlights, research contributions, and so on. To bridge the gap among scientific contributions, leadership and administrative efforts, and the perspective of the general public, Vigyan Prasar is continuously reaching out to its audiences in the shape of a regular e-newsletter, taking its mandate of science communication, popularisation and extension to the next level. Our effort is firmly based on the fact that “Science gathers knowledge faster than society gathers wisdom”. The steady increase in the number of recoveries and the significant and continuous decrease in positivity rate provide us the much-needed assurance that this may be the outcome of improving the health infrastructure and making health the cornerstone at the policy level. We wish an engaging reading to our audiences across all strata of the society and look forward to suggestions and feedback at [email protected]. -
Event Summary Report
1 EVENT SUMMARY REPORT INDIA-NIGERIA: FACING THE COVID-19 PANDEMIC TOGETHER Date: March 30, 2021 Time: 1030-1315 (WAT) Venue: Cisco Webex Virtual Platform Recording Link: https://www.youtube.com/watch?v=L8FpbwhgUdA 1. INTRODUCTION 1.1 The webinar was the first event to be co-hosted by the Gusau Institute (GI) in Nigeria and the Manohar Parrikar Institute for Defence Studies and Analyses (MP-IDSA) in India, and it concentrated on ways to join forces in the fight against COVID-19. Other areas of potential and/ or expanded collaboration were also highlighted during the deliberations. 1.2 The event was divided into two sessions that focused on identifying areas of cooperation between Nigeria and India in controlling the COVID-19 pandemic, and emerging India-Africa cooperation, respectively. The discussions were preceded by an inaugural session co-chaired by the founder of the GI, and the Director General of MP-IDSA, who also led the rest of the programme. (Note: Short profiles of all the participants are attached as Annexure A.) 2. PROGRAMME HIGHLIGHTS 2.1 INAUGURAL SESSION 2.1.1 Opening Remarks by Amb. Sujan R. Chinoy Director General, MP-IDSA https://www.youtube.com/watch?v=L8FpbwhgUdA (0:45-12:34) 2.1.1.1 Copy of the DG’s remarks follows: Lt. Gen. Aliyu Gusau Mohammed, Founder, Gusau Institute, Amb Abhay Thakur, High Commissioner of India to Nigeria, Mr. Boss Mustapha, Secretary to the Government of the Federation (SGF) & Chairman, Presidential Task Force on COVID-19, Experts from Gusau Institute, Distinguished participants, Good afternoon, 2 Today, we have gathered for the first bilateral event, albeit in virtual mode, between the Manohar Parrikar Institute for Defence Studies and Analyses and the Gusau Institute of Nigeria. -
Vaccine Matri: a New Way of Diplomacy
AN EXPLORATORY STUDY OF ROLE OF INDIA IN VACCINE DIPLOMACY FOR COVID-19 PANDEMIC ERA Turkish Online Journal of Qualitative Inquiry (TOJQI) Volume 12, Issue 3, June 2021:652- 665 Research Article An Exploratory Study Of Role Of India In Vaccine Diplomacy For Covid-19 Pandemic Era Dr. Saroj Choudhary1, Dr Sanjiv Singh Bhadauria2, Mr Abhinav Upadhyay3, Dr Sandeep Kulshrestha4 Abstract Coronavirus is spread in end of December, 2019 in Wuhan and in March, 2020 World Health Organization declared it as a pandemic. Coronavirus affect world in many ways like socially, economically and in many other. In early January, 2021 India make their vaccine and not only vaccinated their own people but also help other countries and provide vaccine to their neighbouring countries on grant and commercial basis and this will help India to make their reputation in world platform. In this paper, Vaccine Maîtri an initiative by India to provide vaccine to their neighbouring countries and also other needy countries and how this will enhance the image of India in world stage. Keywords: Coronavirus; COVID-19; vaccine maîtri; vaccine; India;government; WHO. VACCINE MATRI: A NEW WAY OF DIPLOMACY COVID-19 is a major global public health challenge, and in many countries it has created a serious social, economic, and political crisis. The numbers involved are staggering, whether they refer to infection and death, the rate of public health measures such as travel restrictions, or the economic consequences of unemployment and public sector spending. All economies are placed in drug-induced comas, the complex public health systems have become increasingly prevalent in levels of public adherence or surprising disobedience, and health care systems and provinces are being tested by many who have never seen it. -
White Paper on the Management of COVID-19 by the Government of India
White Paper on the Management of COVID-19 by the Government of India JUNE 2021 TABLE OF CONTENTS 1. Executive Summary…………………………………………... (i) 2. The Need for a White Paper on the Management of the COVID-19 Pandemic………………………………….. 1 3. Early Inaction Against COVID-19………………………….. 5 4. Policy Response to the First Wave………………………… 10 5. Hubris and Political Avarice………………………………… 18 6. Ignoring the Signs and the Science………………………... 27 7. Unforgivable Negligence…………………………..…………. 41 8. Vaccine Mismanagement..……………………………...…… 51 9. Wider Impact of Policy Failures…………………………….. 82 10. The Way Ahead……………………………………………….. 89 11. Annexure 1. Indian National Congress: Compendium of Statements, Letters and Resolutions on COVID-19 (March 2020 - June 2021)…………………………………… A1 Executive Summary The mismanagement of the COVID-19 pandemic has been independent India’s gravest governance failure. The Union government under Prime Minister Narendra Modi did not take adequate measures to prevent and contain the pandemic. Therefore, there is a Need for a White Paper (Chapter-1) that examines the government’s acts of omission and commission, its impact on India and suggests constructive measures to improve policy responses to the current and future waves of the pandemic. The Modi government’s handling of the COVID-19 crisis began with its Early Inaction in January 2020 (detailed in Chapter-2). The government ignored early warnings from experts and political leaders from the Opposition. It failed to learn from the lessons and response models of other countries which had been hit by the pandemic. It did not scale up nationwide the lessons from Kerala’s experience in successfully suppressing a virus outbreak (the Nipah virus). -
Announcement on Procurement Process
Announcement on Procurement Process During the past few weeks, there have been reports in the media at large misrepresenting the procurement process of COVAXIN®, in Brazil and other countries. We wish to provide the following clarification - ∙ The procurement process for COVID-19 vaccines and several vaccines for routine immunization follow a common process which is widely accepted, and established in Industry ∙ Based on a country’s requirement, the company receives a letter of intent (or MOU) for procurement ∙ The company then proceeds to apply for emergency use authorization (EUA) in the respective country ∙ Once EUA is received, the Ministry of Health (MOH) would proceed to place a firm order by releasing a purchase order, with the required initial quantities. In several countries, MOHs have placed orders for procurement prior to the approval of vaccines such as USA, EU, India, etc. However, procurement happens only post EUA. ● In order to secure a firm Purchase Order from the country, the company proceeds to raise a Pro Forma Invoice to the MOH, towards the supply of vaccine ● Based on the invoice, the MOH pays the amount in advance ● Once the payment is received, the company proceeds to supply the agreed quantities and within the agreed timelines ● In the specific case of procurement of COVAXIN® by MOH Brazil, since the first meetings with MOH Brazil during Nov 2020, until 29th of June 2021, a step-by-step approach has been followed towards contracts, and regulatory approvals, during this ~ 8 long month-long process. On 4th June 2021, ANVISA authorized the exceptional import of the Covaxin vaccine by the Ministry of Health for distribution and Use Under Controlled Conditions”. -
The-Recitals-January-2021-Vajiram.Pdf
INDEX Message From The Desk Of Director 1 1. Feature Article 2-7 a. Future Of Food b. Vaccine Maitri Initiative 2. Mains Q&A 12-25 3. Prelims Q&A 26-67 4. Bridging Gaps 68-123 1. Vertical and Horizontal Reservations 2. Plea To Bar Disqualified Lawmakers From Contesting Bye-Polls To Same House 3. The India Justice Report 2020 4. Adultery Law And The Armed Forces 5. Urban Local Bodies (ULB) Reforms 6. PRAGATI Meeting 7. Toycathon 8. Henley Passport Index 9. GAVI Board 10. National Girl Child Day 11. Satyameva Jayate Programme 12. Smart Classes For Rural Schools VAJIRAM AND RAVI The Recitals (January 2021) 13. Special Marriage Act 14. Freight Portal 15. Agri-Hackathon 2020 16. Investment Trends Monitor 17. Bad Banks 18. Scheme For Ethanol Distillation 19. Trade Deficit With China 20. Pradhan Mantri Kaushal Vikas Yojana 3.0 21. Regulatory Structure For NBFCs 22. Startup India Seed Fund 23. Kala Utsav 2020 24. Oldest Cave Art 25. Jallikattu 26. Gulf Leaders Sign Solidarity and Stability Deal 27. Russia Withdraws from Open Skies Treaty 28. Scottish Independence Referendum 29. China Holds Third South Asia Multilateral Meet 30. US President Donald Trump Impeached 31. US Eases Restrictions on Contact with Taiwan 32. New START Treaty 33. UAE’s New Citizenship Policy 34. Article 19 of UN Charter 35. H-1B Visas and New Wage-based Rules 36. India at the UN High Table 37. India - UK Cooperation Against Cross-Border Terrorism 38. India-France to Expand Ecological Partnership 39. Document on the U.S. Strategic Framework for the Indo-Pacific 40. -
ETA Episode 85 Transcript
Ear to Asia podcasts Title: India's soft power push with vaccine diplomacy Description: India is the world’s largest donor of COVID-19 vaccines despite having the world’s second highest caseload of coronavirus. What are India’s motivations for this bold move? Will India have enough vaccines for its 1.3+ billion people, and what does India’s apparent generosity say about the vaccine nationalism of the west? Political scientist Dr Pradeep Taneja and health policy researcher Dr Azad Bali join presenter Ali Moore to examine India’s vaccine diplomacy. An Asia Institute podcast. Listen: https://player.whooshkaa.com/episode?id=796941 Ali Moore: Hello, I'm Ali Moore. This is Ear to Asia. Azad Bali: There is some sense of competition between India and China with regards to this global outreach with vaccines, but I think India has a stronger track record in this space of manufacturing vaccines at a larger scale and that are affordably priced. Pradeep Taneja: The supporters of Prime Minister Modi, of which there are many, are quite proud for India to supply vaccines to other countries but others have been critical of both the roll out of the vaccination program at home, and of this big-noting of the Modi government to try and tell the world that India is the pharmacy to the rest of the world. Ali Moore: In this episode, home and away, India's vaccine rollout on the world stage. Ear to Asia is the podcast from Asia Institute, the Asia research specialist at the University of Melbourne. -
Bhutan's Experience with COVID-19 Vaccination in 2021
Commentary Bhutan’s experience with COVID-19 BMJ Glob Health: first published as 10.1136/bmjgh-2021-005977 on 18 May 2021. Downloaded from vaccination in 2021 1 2 Thinley Dorji , Saran Tenzin Tamang To cite: Dorji T, Tamang ST. INTRODUCTION Summary box Bhutan’s experience with As of April 2021, COVID-19 cases continue COVID-19 vaccination in 2021. BMJ Global Health to rise globally and in the South Asia region ► COVID-19 has caused a major socioeconomic im- 2021;6:e005977. doi:10.1136/ causing devastating morbidity, mortality and pact on the lives of people in Bhutan, a landlocked bmjgh-2021-005977 disruption of socioeconomic life. Apart from nation situated in the eastern Himalayas. public health measures to prevent spread of ► The pandemic has led to the closure of its inter- national border, restriction on cross- border trade, Received 11 April 2021 COVID-19, significant investment has been closure of businesses, schools and colleges, and Revised 20 April 2021 made to develop, test and roll out vaccines. Accepted 23 April 2021 Modelling studies predict significant reduc- restrictions on social gatherings. tion in overall attack rates by SARS- CoV-2 ► Bhutan has reported 957 cases of COVID-19 with one death as of 18 April 2021. through use of effective COVID-19 vaccines, ► Despite limitations of resources and experiences, with the highest relative reduction among Bhutan has achieved good control of the pandemic older adults (aged 65 years and older), reduc- through its unique public health approaches. 1 tion of intensive care admissions and deaths. ► Bhutan vaccinated 94% of its adult population with As of 18 April 2021, 14 vaccines have COVID-19 vaccine within a span of two weeks in been approved for human use by at least April 2021. -
India: the World's Pharmacy Expands Its Reach in Global Health
New York | New Delhi | Rio de Janeiro Nairobi | Johannesburg | London India: The World’s Pharmacy Expands Its Reach in Global Health March 2021 This white paper was last updated on 1 March 2021 Global Health Strategies 18/1, 2nd Floor Shaheed Bhawan, Aruna Asaf Ali Marg, New Delhi, 110 067 www.globalhealthstrategies.com Twitter: @GHS Contents Executive Summary 02 India’s response to COVID-19 03 ∙ Pharmaceuticals and Biosimilars 04 ∙ Vaccines 05 ∙ Diagnostics 06 Evolution of India’s pharmaceutical industry 07 ∙ Milestones 08 Case Studies ∙ Hepatitis B Vaccine 10 ∙ Anti-retroviral Drugs 11 ∙ MenAfriVac 12 ∙ Complex Generics 13 ∙ Insulin 14 ∙ Monoclonal Antibodies 15 ∙ Vaccine for Rotavirus 16 ∙ Typhoid Conjugate Vaccine 17 Conclusion: Looking Forward 18 Executive Summary India’s pharmaceutical industry is already playing a pivotal role in the scale-up of pharmaceuticals and diagnostics to combat the global COVID-19 pandemic. It is poised to play an even more dominant role as biological products – preventive vaccines and cutting-edge biotechnology such as monoclonal antibodies– come to the fore. Even before the pandemic, Indian manufacturers produced vast quantities of generic antiviral drugs that turned HIV from a death sentence to a chronic manageable condition in developing countries. India’s global dominance in generic drugs and vaccine manufacturing has earned it the label “Pharmacy of the World”. COVID-19 only strengthens the case for this moniker. So far, India has supplied medicines to 133 countries to fight the pandemic. Six Indian manufacturers have been granted royalty-free licenses by Gilead to manufacture the first antiviral drug approved by the U.S.